160 related articles for article (PubMed ID: 36900841)
1. Multidimensional Results and Reflections on CAR-T: The Italian Evidence.
Foglia E; Garagiola E; Ladisa V; Rambaldi A; Cairoli R; Sammassimo S; Salè EO; Zinzani PL; Esposti M; Alberti L; Mulas MF; Melis E; Onnis S; Marcias M; Satta V; Croce D
Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36900841
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
4. Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study.
Cavallo MC; Cavazza M; Bonifazi F; Casadei B; Cutini I; Tonietti B; Saccardi R; Zinzani P; Jommi C
BMC Health Serv Res; 2024 Jan; 24(1):121. PubMed ID: 38254079
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
6. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future.
Heine R; Thielen FW; Koopmanschap M; Kersten MJ; Einsele H; Jaeger U; Sonneveld P; Sierra J; Smand C; Uyl-de Groot CA
Hemasphere; 2021 Feb; 5(2):e524. PubMed ID: 33880433
[TBL] [Abstract][Full Text] [Related]
7. Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center.
Chacim S; Monjardino T; Cunha JL; Medeiros P; Redondo P; Bento MJ; Mariz JM
PLoS One; 2022; 17(12):e0278950. PubMed ID: 36490296
[TBL] [Abstract][Full Text] [Related]
8. Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma.
Ring A; Grob B; Aerts E; Ritter K; Volbracht J; Schär B; Greiling M; Müller AMS
Ann Hematol; 2022 Aug; 101(8):1755-1767. PubMed ID: 35759026
[TBL] [Abstract][Full Text] [Related]
9. Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Snyder S; Chung KC; Jun MP; Gitlin M
Adv Ther; 2021 Sep; 38(9):4659-4674. PubMed ID: 34302277
[TBL] [Abstract][Full Text] [Related]
10. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
12. [Economics and management of CAR T- cell therapy : Status quo and future perspectives].
Kron F; Franz J; Kron A; Hallek M
Internist (Berl); 2021 Jun; 62(6):620-626. PubMed ID: 33944969
[TBL] [Abstract][Full Text] [Related]
13. Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Snyder S; Albertson T; Garcia J; Gitlin M; Jun MP
Adv Ther; 2021 Aug; 38(8):4541-4555. PubMed ID: 34279805
[TBL] [Abstract][Full Text] [Related]
14. [Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].
Amato L; Colais P; Davoli M; Ferroni E; Fusco D; Minozzi S; Moirano F; Sciattella P; Vecchi S; Ventura M; Perucci CA
Epidemiol Prev; 2013; 37(2-3 Suppl 2):1-100. PubMed ID: 23851286
[TBL] [Abstract][Full Text] [Related]
15. Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Broder MS; Ma Q; Yan T; Zhang J; Chang E; Kuzan D; Eldjerou L
Am Health Drug Benefits; 2020; 13(5):192-199. PubMed ID: 33343819
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study.
Solano C; Castro-Rebollo P; Pérez-Martínez A; López-Corral L; Barba-Suñol P; Kwon M; Ortiz V; Sanz-Caballer J; Caballero AC; Martínez J; Cedillo Á; Sureda A
BMJ Open; 2023 Jul; 13(7):e071371. PubMed ID: 37491085
[TBL] [Abstract][Full Text] [Related]
17. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Jalbert JJ; Wu N; Chen CI; Ambati S; Ge W; Arnason JE
Adv Ther; 2022 Jun; 39(6):2630-2640. PubMed ID: 35397110
[TBL] [Abstract][Full Text] [Related]
18. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
[TBL] [Abstract][Full Text] [Related]
19. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Hoda D; Richards R; Faber EA; Deol A; Hunter BD; Weber E; DiFilippo H; Henderson-Clark T; Meaux L; Crivera C; Riccobono C; Garrett A; Jackson CC; Fowler J; Theocharous P; Stewart R; Lorden AL; Porter DL; Berger A
Future Oncol; 2022 Jun; 18(19):2415-2431. PubMed ID: 35583358
[TBL] [Abstract][Full Text] [Related]
20. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
